News

Devyser among Sweden’s Best Workplaces

We are extremely proud to have been recognized, once again, as one of Sweden’s Best Workplaces! This is a wonderful recognition of the teamwork and spirit that our colleagues exhibit every day, making Devyser a great place to work! Link to the list (small organisations)

Devyser completes private placement of SEK 130 million to Swedbank Robur and AP4

Stockholm, February 2, 2021 – Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announced the completion of a private placement of 7,465 shares, corresponding to SEK 130 million before issuance costs, to Swedbank Robur and the Fourth Swedish National Pension Fund (AP4). The purpose of the issue is primarily to finance the company’s …

Devyser completes private placement of SEK 130 million to Swedbank Robur and AP4 Read More »

Devyser receives Eurostars grant to develop novel DNA test for early detection of transplant rejection

Devyser has been awarded a funding of EUR 750,000 through the Eurostars-2 program and will join its efforts with the University Hospital of Zurich to further develop its unique NGS based test for early detection of kidney transplant recipients. Through this project, Devyser aims to provide a certified CE-IVD kit, including reagents, protocols and software …

Devyser receives Eurostars grant to develop novel DNA test for early detection of transplant rejection Read More »

Case Study – A new NGS-based method for chimerism monitoring

New methods for mixed chimerism analytics are transforming post-transplant monitoring, enabling earlier detection of relapse and initiation of treatment to improve and save the lives of transplanted patients. Dr. Dan Hauzenberger, Medical Director, Section of Transplantation Immunology at Sweden’s Karolinska University Hospital, shares why Karolinska decided to replace their STR-PCR and qPCR methods with a …

Case Study – A new NGS-based method for chimerism monitoring Read More »

Devyser at DGTI 2020

Come and visit our virtual booth at DGTI! The 53rd annual meeting in Immunohaematology and Transfusion Medicine is taking place virtually from September 16th to 18th 2020. Visit our virtual booth to learn more about our upcoming solution for the non-invasive detection of fetal RHD status as well as Devyser Chimerism, our chimerism monitoring solution. …

Devyser at DGTI 2020 Read More »

Devyser’s breakthrough NGS product for hereditary breast and ovarian cancer testing now approved for diagnostic use in the EU

Stockholm, 22 July 2020 —Swedish genetic test developer Devyser’s product for hereditary breast and ovarian cancer (HBOC) is now CE labelled and approved for diagnostic use in the EU. The kit is based on Devyser’s patented next-generation sequencing library prep technology and provides targeted sequencing of 12 genes with a recognized connection to the development …

Devyser’s breakthrough NGS product for hereditary breast and ovarian cancer testing now approved for diagnostic use in the EU Read More »

Discover Devyser CFTR 68

https://vimeo.com/434385139/77bd5832b6 Discover Devyser CFTR 68, our latest kit for the analysis of the CFTR gene, capable of detecting up to 68 mutations most commonly associated with Cystic Fibrosis. List of mutations detected by Devyser CFTR 68 711+ 1G>T, 2043delG, 1677delTA, W1282X, R1283M, K710X, 3849+10kbC>T, 2789+5G>A, M1101K, G85E, 3905insT, 1525-1G>A, 2184delA, 3659delC, N1303K, 2184insA, 1812-1G->A, CFTRdele2,3, …

Discover Devyser CFTR 68 Read More »